Eli Lilly pins injectable migraine med Emgality against Biohaven's oral rival Nurtec ODT in head-to-head study

Eli Lilly pins injectable migraine med Emgality against Biohaven's oral rival Nurtec ODT in head-to-head study

Source: 
Fierce Pharma
snippet: 

When the FDA awarded Biohaven Pharmaceuticals’ migraine med Nurtec ODT with a second indication last month, the company paraded the drug as the only option to both prevent and treat migraines. Now, Eli Lilly wants to pin its rival antibody against Biohaven’s pill as a prevention option for lower-frequency migraine patients.